University Children's Hospital Zurich Reports Findings in Rhabdomyosarcomas [Evaluation of the role of AXL in fusion-positive pediatric rhabdomyosarcoma identifies the small-molecule inhibitor bemcentinib (BGB324) as potent chemosensitizer].
In: Pediatrics Week, 2024-03-28, S. 679-679
serialPeriodical
Zugriff:
A recent study conducted at the University Children's Hospital Zurich in Switzerland has found that rhabdomyosarcoma (RMS), a highly aggressive pediatric cancer, often fails to respond to chemotherapy treatment. The study focused on the role of the AXL receptor tyrosine kinase (AXL) in RMS tumorigenesis, migration, and chemotherapy response. The researchers discovered that targeting AXL with small molecule inhibitors, such as bemcentinib (BGB324), cabozantinib, and NPS-1034, could enhance the efficacy of chemotherapy drugs and rapidly kill RMS cells. The combination of bemcentinib and vincristine showed strong anti-tumoral activity in a mouse model, reducing tumor burden significantly. This research suggests that bemcentinib may be a promising drug to improve chemotherapy efficacy in RMS patients. [Extracted from the article]
Copyright of Pediatrics Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
University Children's Hospital Zurich Reports Findings in Rhabdomyosarcomas [Evaluation of the role of AXL in fusion-positive pediatric rhabdomyosarcoma identifies the small-molecule inhibitor bemcentinib (BGB324) as potent chemosensitizer].
|
---|---|
Zeitschrift: | Pediatrics Week, 2024-03-28, S. 679-679 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1944-2637 (print) |
Schlagwort: |
|
Sonstiges: |
|